Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | TGF beta signal transducer SmadC | 0.001 | 0 | 0.5 |
Echinococcus granulosus | smad | 0.001 | 0 | 0.5 |
Schistosoma mansoni | TGF-beta signal transducer Smad2 | 0.001 | 0 | 0.5 |
Trypanosoma cruzi | telomerase reverse transcriptase, putative | 0.0171 | 0.2616 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.2179 | 0.3016 |
Plasmodium vivax | telomerase reverse transcriptase, putative | 0.0171 | 0.2616 | 0.5 |
Giardia lamblia | Telomerase catalytic subunit | 0.0171 | 0.2616 | 0.5 |
Leishmania major | telomerase reverse transcriptase, putative | 0.0171 | 0.2616 | 0.5 |
Echinococcus multilocularis | Smad4 | 0.001 | 0 | 0.5 |
Trypanosoma brucei | telomerase reverse transcriptase | 0.0171 | 0.2616 | 0.5 |
Toxoplasma gondii | RNA-directed DNA polymerase | 0.0171 | 0.2616 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0 | 0.5 |
Echinococcus multilocularis | mothers against decapentaplegic 5 | 0.001 | 0 | 0.5 |
Brugia malayi | Telomerase reverse transcriptase | 0.0455 | 0.7225 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.2179 | 1 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0 | 0.5 |
Trypanosoma cruzi | telomerase reverse transcriptase, putative | 0.0171 | 0.2616 | 0.5 |
Echinococcus granulosus | TGF beta signal transducer SmadC | 0.001 | 0 | 0.5 |
Schistosoma mansoni | smad | 0.001 | 0 | 0.5 |
Plasmodium falciparum | telomerase reverse transcriptase | 0.0171 | 0.2616 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.2179 | 1 |
Echinococcus multilocularis | smad | 0.001 | 0 | 0.5 |
Schistosoma mansoni | Smad4 | 0.001 | 0 | 0.5 |
Echinococcus granulosus | mothers against decapentaplegic 5 | 0.001 | 0 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0 | 0.5 |
Echinococcus granulosus | Smad4 | 0.001 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 23.0999 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.